Nobuichi Kuribayashi
Overview
Explore the profile of Nobuichi Kuribayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yamamoto T, Tanaka M, Kuribayashi N, Okuguchi F, Isotani H, Iwamoto M, et al.
Clin Exp Dent Res
. 2020 Dec;
7(4):419-428.
PMID: 33258300
Objectives: Cardiovascular disease remains the most common cause of death in patients with type 2 diabetes mellitus. Because periodontitis is a risk factor of cardiovascular disease, identification of risk factors...
12.
Yokoyama H, Shiraiwa T, Takahara M, Iwamoto M, Kuribayashi N, Nomura T, et al.
BMJ Open Diabetes Res Care
. 2020 Sep;
8(1).
PMID: 32948539
Introduction: Progression of muscle strength weakening will lead to a poor physical performance and disability. While this is particularly important in patients with diabetes, the associations of reduced muscle strength...
13.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al.
Cardiovasc Diabetol
. 2020 Jul;
19(1):110.
PMID: 32646498
Background: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular...
14.
Tanaka M, Yamamoto T, Kuribayashi N, Okuguchi F, Isotani H, Iwamoto M, et al.
Diabetol Int
. 2020 Mar;
11(2):121-128.
PMID: 32206482
Background: Our previous pilot study using patients with type 2 diabetes mellitus in one medical clinic showed an association of urinary albumin excretion, a marker of generalized vascular dysfunction and...
15.
Watanabe Y, Kuribayashi N, Uchida D, Suzuki D, Kato M, Nagayama D, et al.
Diabetes Ther
. 2020 Feb;
11(3):753.
PMID: 32052282
In the original article, the 6th sentence of the section "FD and calorie intake" is incorrect. The correct sentence is "The protein component of FD consists of whey protein, casein,...
16.
Yokoyama H, Yamamoto T, Tanaka M, Kudo C, Hidaka K, Kuribayashi N, et al.
Diabetol Int
. 2019 Oct;
10(4):250-259.
PMID: 31592401
Diabetes and periodontitis may increase risk of cardiovascular disease. Whether albuminuria, C-reactive protein (CRP), and socioeconomic factors, known as cardiovascular risks in subjects with poorly controlled diabetes, are independently associated...
17.
Watanabe Y, Kuribayashi N, Uchida D, Suzuki D, Kato M, Nagayama D, et al.
Diabetes Ther
. 2018 Dec;
10(1):311-321.
PMID: 30574667
Introduction: Sodium-dependent glucose transporter-2 (SGLT2) inhibitors such as dapagliflozin induce weight loss, but the mechanism is thought to involve loss of both body fat and skeletal muscle mass. The decrease...
18.
Kudo C, Shin W, Sasaki N, Harai K, Kato K, Seino H, et al.
Odontology
. 2018 Feb;
106(3):349.
PMID: 29464471
Unfortunately, in Table-5 of the original article, the parameter in the 5th row was published incorrectly as "LDL-C (mg/dL)". The correct parameter should read as "HDL-C (mg/dL)".
19.
Kudo C, Shin W, Sasaki N, Harai K, Kato K, Seino H, et al.
Odontology
. 2018 Jan;
106(3):316-327.
PMID: 29330707
Atherosclerosis, a chronic inflammatory disease in arterial blood vessels, is one of the major causes of death in worldwide. Meanwhile, periodontal disease is a chronic inflammatory disease caused by infection...
20.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al.
Diabetes Ther
. 2017 Sep;
8(5):999-1013.
PMID: 28864997
Introduction: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are anti-diabetic agents that improve glycemic control with a low risk of hypoglycemia and ameliorate a variety of cardiovascular risk factors. The aim of the...